Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD

BER MGMT MMR MSH6 NAD+ PARG inhibition PARP activation TMZ resistance glioblastoma temozolomide

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
22 Jul 2022
Historique:
received: 14 06 2022
revised: 17 07 2022
accepted: 20 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Glioblastoma multiforme (GBM) is an incurable brain cancer with an average survival of approximately 15 months. Temozolomide (TMZ) is a DNA alkylating agent for the treatment of GBM. However, at least 50% of the patients treated with TMZ show poor response, primarily due to elevated expression of the repair protein O

Identifiants

pubmed: 35892832
pii: cancers14153572
doi: 10.3390/cancers14153572
pmc: PMC9331395
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : R01 CA148629
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA238061
Pays : United States
Organisme : National Science Foundation
ID : NSF-1841811
Organisme : NIH HHS
ID : ES029518, CA148629, ES014811, ES028949, CA238061, CA236911, AG069740 and ES032522
Pays : United States

Références

Cancer Res. 2019 Sep 1;79(17):4331-4338
pubmed: 31273061
J Neurooncol. 2003 Feb;61(3):203-7
pubmed: 12675312
Sci Adv. 2019 Apr 10;5(4):eaav4340
pubmed: 30989114
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6767-71
pubmed: 16203762
Neuro Oncol. 2014 Oct;16(10):1313-23
pubmed: 24811392
Neuro Oncol. 2009 Jun;11(3):281-91
pubmed: 18952979
Clin Cancer Res. 2009 Jul 15;15(14):4622-9
pubmed: 19584161
Cancer Res. 2006 Apr 15;66(8):3987-91
pubmed: 16618716
Cancer Res. 1994 Feb 1;54(3):649-52
pubmed: 8306326
DNA Repair (Amst). 2020 Sep;93:102930
pubmed: 33087267
Cell Rep. 2014 Sep 25;8(6):1819-1831
pubmed: 25220464
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6443-7
pubmed: 8692834
Br J Cancer. 2019 Oct;121(7):545-555
pubmed: 31413318
Cell Rep. 2021 Nov 2;37(5):109917
pubmed: 34731617
NAR Cancer. 2021 Nov 17;3(4):zcab044
pubmed: 34806016
Cancer Res. 2015 Oct 15;75(20):4416-28
pubmed: 26282173
Front Oncol. 2021 Oct 27;11:745981
pubmed: 34778062
Mol Cancer Res. 2021 Feb;19(2):207-214
pubmed: 33257507
Cancer Res. 2005 Jul 15;65(14):6394-400
pubmed: 16024643
Eur J Cancer. 2005 Dec;41(18):2948-57
pubmed: 16288862
Int J Cancer. 2011 Aug 1;129(3):659-70
pubmed: 21425258
Neuro Oncol. 2020 Jun 9;22(6):875-885
pubmed: 32009149
Nucleic Acids Res. 2011 Jul;39(12):5045-56
pubmed: 21398629
DNA Repair (Amst). 2022 Apr;112:103303
pubmed: 35219626
Carcinogenesis. 1985 Dec;6(12):1823-6
pubmed: 4064256
Nat Rev Cancer. 2016 Jan;16(1):20-33
pubmed: 26678314
Clin Cancer Res. 2004 Jun 1;10(11):3728-36
pubmed: 15173079
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Sci Rep. 2020 Jan 20;10(1):651
pubmed: 31959836
Clin Neurosurg. 2008;55:165-71
pubmed: 19248684
Cancer Res. 2005 Jun 1;65(11):4861-9
pubmed: 15930307
Sci Rep. 2018 Feb 9;8(1):2771
pubmed: 29426857
DNA Repair (Amst). 2007 Jun 1;6(6):695-711
pubmed: 17337257
Mol Cell. 2004 Apr 9;14(1):105-16
pubmed: 15068807
CA Cancer J Clin. 2021 Sep;71(5):381-406
pubmed: 34427324
J Clin Oncol. 2007 Jun 20;25(18):2540-5
pubmed: 17577032
Cancers (Basel). 2021 May 24;13(11):
pubmed: 34073837
Cancer Res. 2018 Dec 15;78(24):6713-6716
pubmed: 30498082
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Mol Med Rep. 2012 Feb;5(2):575-9
pubmed: 22086271
Neuro Oncol. 2011 Apr;13(4):384-92
pubmed: 21317208
Neuro Oncol. 2011 May;13(5):471-86
pubmed: 21377995
DNA Repair (Amst). 2007 Aug 1;6(8):1079-99
pubmed: 17485253
Cancer Res. 2011 Mar 15;71(6):2308-17
pubmed: 21406402
J Biol Chem. 1974 Jun 10;249(11):3475-82
pubmed: 4831224
Front Oncol. 2012 Dec 05;2:186
pubmed: 23227453
J Hematol Oncol. 2018 Feb 27;11(1):32
pubmed: 29486795
Biochem Pharmacol. 2019 Apr;162:98-108
pubmed: 30296409
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Nat Rev Mol Cell Biol. 2006 May;7(5):335-46
pubmed: 16612326
Mol Cell Biol. 2002 Nov;22(22):7831-41
pubmed: 12391152
Cell Rep. 2018 May 15;23(7):2095-2106
pubmed: 29768207
Mol Metab. 2019 Dec;30:192-202
pubmed: 31767171
Nucleic Acids Res. 2013 Aug;41(15):7286-301
pubmed: 23775793
Integr Biol (Camb). 2012 Oct;4(10):1237-55
pubmed: 22892544
Cancer Chemother Pharmacol. 2014 Aug;74(2):257-65
pubmed: 24880570
DNA Repair (Amst). 2016 Feb;38:94-101
pubmed: 26704428
Clin Cancer Res. 2007 Apr 1;13(7):2038-45
pubmed: 17404084
Am J Clin Oncol. 2014 Aug;37(4):369-76
pubmed: 23357973
Cancer Res. 2018 Sep 1;78(17):5060-5071
pubmed: 29976574
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cancer Discov. 2020 Nov;10(11):1672-1689
pubmed: 32606138

Auteurs

Jianfeng Li (J)

Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Christopher A Koczor (CA)

Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Kate M Saville (KM)

Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Faisal Hayat (F)

Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Alison Beiser (A)

Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Steven McClellan (S)

Mitchell Cancer Institute Flow Cytometry SRL, University of South Alabama, Mobile, AL 36604, USA.

Marie E Migaud (ME)

Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Robert W Sobol (RW)

Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Classifications MeSH